|
|
|
Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection Dynavax Expands Commercial
and Clinical Leadership
Dynavax Completes Symphony Dynamo Acquisition Dynavax's
European Manufacturing Facility Approved for Commercial Production of HEPLISAV Hepatitis B Surface Antigen Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy Dynavax to Acquire Symphony Dynamo, Including $20 Million in Unrestricted Cash |
Our clinical-stage pipeline includes 3 product candidates for the prevention and treatment of infectious diseases. More...
|
Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.
Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Novartis, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.
Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
|
 |
